NUVA Key Statistics, Chart & Performance
The current stock price of NUVA is 39.75 USD. In the past month the price decreased by -0.62%. In the past year, price decreased by -8.3%.
NUVA Latest News, Press Relases and Analysis
NUVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.15 | 218.22B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.01 | 201.47B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.31 | 145.68B | ||
| SYK | STRYKER CORP | 27.81 | 140.07B | ||
| IDXX | IDEXX LABORATORIES INC | 57.77 | 58.17B | ||
| BDX | BECTON DICKINSON AND CO | 13.37 | 55.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.73 | 48.81B | ||
| RMD | RESMED INC | 25.39 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.23 | 38.11B | ||
| DXCM | DEXCOM INC | 34.79 | 25.24B | ||
| PODD | INSULET CORP | 67.09 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.52 | 18.46B |
Related stock screener links
About NUVA
Company Profile
NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. The company is headquartered in San Diego, California and currently employs 3,000 full-time employees. The company went IPO on 2004-05-13. The firm is focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company offers a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, it develops and sells magnetically adjustable implant systems for the spine and specialized orthopedic procedures. The company also designs and sell expandable growing rod implant systems for the treatment of early-onset scoliosis that can be non-invasively lengthened after implantation with incremental adjustments via an external remote controller using magnetic technology called MAGneticExternal Control (MAGEC). The company operates in more than 50 countries serving surgeons, hospitals, and patients.
Company Info
NUVASIVE INC
7475 Lusk Blvd
San Diego CALIFORNIA 92121 US
CEO: J. Christopher Barry
Employees: 3000
Phone: 18589091800.0
NUVASIVE INC / NUVA FAQ
What does NUVA do?
NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. The company is headquartered in San Diego, California and currently employs 3,000 full-time employees. The company went IPO on 2004-05-13. The firm is focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company offers a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, it develops and sells magnetically adjustable implant systems for the spine and specialized orthopedic procedures. The company also designs and sell expandable growing rod implant systems for the treatment of early-onset scoliosis that can be non-invasively lengthened after implantation with incremental adjustments via an external remote controller using magnetic technology called MAGneticExternal Control (MAGEC). The company operates in more than 50 countries serving surgeons, hospitals, and patients.
What is the stock price of NUVASIVE INC today?
The current stock price of NUVA is 39.75 USD. The price decreased by -2.24% in the last trading session.
Does NUVA stock pay dividends?
NUVA does not pay a dividend.
How is the ChartMill rating for NUVASIVE INC?
NUVA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists NUVA stock?
NUVA stock is listed on the Nasdaq exchange.
NUVA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NUVA. When comparing the yearly performance of all stocks, NUVA turns out to be only a medium performer in the overall market: it outperformed 43.5% of all stocks.
NUVA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NUVA. While NUVA is still in line with the averages on profitability rating, there are concerns on its financial health.
NUVA Financial Highlights
Over the last trailing twelve months NUVA reported a non-GAAP Earnings per Share(EPS) of 2. The EPS increased by 15.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.32% | ||
| ROA | 1.36% | ||
| ROE | 3.19% | ||
| Debt/Equity | 0.89 |
NUVA Forecast & Estimates
22 analysts have analysed NUVA and the average price target is 50.72 USD. This implies a price increase of 27.6% is expected in the next year compared to the current price of 39.75.
For the next year, analysts expect an EPS growth of 13.97% and a revenue growth 6.01% for NUVA